Carbone, Carmine, et al. “TGF-β-Activated Kinase 1 (TAK1) Is an In Vivo Druggable Target for Reverting Pancreatic Cancer Chemoresistance”. JOP. Journal of the Pancreas, vol. 14, no. 5S, Sept. 2013, p. 562, doi:10.6092/1590-8577/1866.